Guwahati: The cost of the nasal Covid-19 vaccine from Bharat Biotech, called iNCOVACC, which will be administered as a booster dose to people over 18 years old, has been approved by the Centre at Rs 800 for private hospitals and Rs 325 for public ones.
The fourth week of January will see the introduction of the iNCOVACC vaccination.
Those who have received Covishield and Covaxin may use the nasal vaccine as a heterologous booster dosage, according to the Union Health Ministry.
The iNCOVACC has been authorised by the Indian government and will be administered to adults over the age of 18 as a heterologous booster dosage.
Private hospitals will offer the vaccine. Both primary series and heterologous booster approval were given to the first intranasal vaccine in history, iNCOVACC.
The initial 2-dose schedule and the heterologous booster dose have both been approved for the first time ever for an intranasal vaccination for covid.
Prior to this, the vaccine had been approved for a main 2-dose regimen for individuals 18 and older in an emergency circumstance with restricted usage. At 14 trial sites across India, the vaccine’s Phase III trials were carried out on 3,100 people to assess its immunogenicity and safety. In this regard, the CoWIN platform will also be changed.
The preparation for COVID19 in several states around the nation has been the subject of high-level talks with senior authorities over the past two days.
The Indian Medical Association and other senior physicians attended a meeting that the Union Health Minister also conducted.